Abstract
Transcatheter aortic valve replacement (TAVR) is quickly becoming the new standard of care for high- and intermediate-risk patients requiring aortic valve replacement. From May 2012 through April 2018, 1850 patients were evaluated for severe aortic valve stenosis, and over 900 TAVR procedures were performed at the author's institution, Allegheny General Hospital, Pittsburgh. Efficient screening processes, comprehensive review of data, and the less invasive delivery of care have made the TAVR program a viable and sustainable treatment option for patients with severe symptomatic aortic valve stenosis. Developing an efficient and dedicated process for patient evaluation and delivery of care with reevaluation for leaner processes ensures the efficacy and good patient outcomes of a TAVR program.